Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

NCT02069080 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

2

Enrollment

NIH

Sponsor class

Conditions

Cancer

Interventions

DRUG: 64-Cu-plerixafor

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]